STERIS (STE) shares are back in focus after third quarter results topped revenue expectations, matched profit forecasts, and were accompanied by reaffirmed full year guidance, giving investors fresh information on the company’s operating momentum.
See our latest analysis for STERIS.
At a share price of $248.35, STERIS has a 1-day share price return of 1.69% and a softer 30-day share price return of a 7.56% decline. Its 1-year total shareholder return of 14.36% and 5-year total shareholder return of 48.13% point to steadier long term progress that recent earnings and the ongoing buyback appear to have brought back into focus.
If this earnings update has you thinking about other healthcare opportunities tied to long term procedure volumes and infrastructure needs, take a look at our 25 healthcare AI stocks as a starting list to research.
With STERIS posting steady earnings progress, ongoing buybacks and a recent pullback in the share price, the key question now is whether you are looking at an underappreciated healthcare compounder or a stock where the market is already pricing in future growth.
Most Popular Narrative: 11.8% Undervalued
STERIS's most followed narrative pegs fair value at $281.63 per share versus the last close of $248.35, setting up an interesting gap for investors to interpret.
Continued expansion of STERIS's consumables and services segments with high recurring revenue and margin visibility positions the company to benefit from increasing healthcare expenditures and adoption of best-practice infection control standards, supporting both revenue and margin expansion.
Curious what kind of revenue pace, margin profile, and future earnings multiple need to line up for that fair value to make sense over time? The most popular narrative lays out a detailed path using specific growth, profitability, and valuation assumptions that go well beyond a simple price target headline.
Result: Fair Value of $281.63 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, tariff pressures and any drag from healthcare reimbursement or capital spending could quickly challenge the upbeat margin and growth assumptions behind that fair value gap.
Find out about the key risks to this STERIS narrative.
Another Way To Look At Valuation
That 11.8% undervaluation story rests on future earnings and multiples, but the current P/E of 34.4x tells a different story. It sits above the US Medical Equipment industry at 30.4x, the peer average at 25.4x, and even our fair ratio of 28.7x, which points to valuation risk if expectations soften. So which signal do you trust more: the narrative gap or the richer multiple?
See what the numbers say about this price — find out in our valuation breakdown.
Build Your Own STERIS Narrative
If you look at these numbers and reach a different conclusion, or simply prefer to test your own assumptions, you can build a custom view of STERIS in just a few minutes using our Do it your way tool.
A good starting point is our analysis highlighting 2 key rewards investors are optimistic about regarding STERIS.
Looking for more investment ideas?
If you are weighing your next move, do not stop at one stock. A few minutes with the right screen could surface ideas you will wish you had seen earlier.
- Target potential bargains that combine quality and attractive pricing by scanning our 54 high quality undervalued stocks and see which names deserve a closer look.
- Strengthen the core of your portfolio with companies that prioritize financial resilience using the solid balance sheet and fundamentals stocks screener (44 results) as your filter for sturdier options.
- Spot lesser known opportunities that still show solid fundamentals by running the screener containing 24 high quality undiscovered gems and get ahead of where attention might go next.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com